Phenomenex has introduced two polysaccharide-based Lux Columns for HPLC/SFC chiral separations.
This brings the company's total to five Lux phases, which together form a set with a range of selectivity to resolve 92 per cent of enantiomers.
The new Lux Cellulose-4 is a novel cellulose tris (4-chloro-3-methylephenylcarbamate) phase and the Lux Cellulose-3 uses cellulose tris (4-methylbenzoate) as the selector.
Both new columns deliver high efficiency and loading capacity and are pressure-stable up to 300 bar.
Phenomenex has designed a chiral method development wall poster to help guide users through simple screening protocols, and customers can create their own three-, four- or five-phase screening kits.
Phenomenex also offers HPLC and SFC chiral screening and separation services.
After resolving the chiral compound, Phenomenex provides a report detailing the optimal phase and method conditions to the service customer.
The FDA mandates that enantiomers of all chiral drugs in development be screened separately on their pharmacodynamic and pharmacokinetic properties.
The identification of chiral molecules is also important in toxicology studies, flavour and fragrance analysis, and environmental applications such as pesticide analysis.
Lux columns are offered in 3 and 5um particle sizes, packed for analytical-scale use or Axia-packed for preparative applications.
20um bulk media is also available up to the kilogram scale.
